药明康德董事长李革博士荣获CPhI“2019年度CEO”

制药界 · 公众号 · 药品 · 2019-11-11 09:18

正文

新法规下质量年度回顾年度报告制度及工艺变更管理

重点培训：药品研发质量体系建立

原料药制备工艺研究

2020版药典相关解读与各部难点实践分析

▎药明 康德/报道

药明康德董事长李革博士荣获CPhI“2019年度CEO”

2019年11月11日——全球知名的世界制药原料博览会（CPhI）日前公布2019年度奖项（CPhI Pharma Awards）评选结果，药明康德董事长兼首席执行官李革博士凭借为全球生物医疗研发领域做出的卓越贡献，荣获“年度CEO”称号。

CPhI是世界上最大的医药行业盛会之一，今年的CPhI全球大会（CPhI Worldwide）吸引了超过45,000名业内人士参会。CPhI年度奖项旨在表彰那些坚持不懈、开拓创新，为推动行业发展做出重要贡献的企业与个人。奖项评审委员会独立客观，由全球多位资深专家组成。

评委会表示，在李革博士的带领下，药明康德已成为全球医药创新领域备受尊崇的赋能者，为医疗健康行业的发展做出了卓越的贡献。如今，药明康德开放式、一体化赋能平台正承载着全球30多个国家，3700多个合作伙伴的研发创新项目，不断加速新药研发进程，为患者带来突破性的治疗方案。

“我很高兴获此殊荣，也特别感谢评委会对药明康德全球化赋能平台的认可，”药明康德董事长兼首席执行官李革博士表示，“我们非常荣幸能够帮助全球创新合作伙伴提升研发效率，让更多新药、好药早日进入市场，造福全球病患。”

关于药明康德
药明康德（股票代码：603259.SH/2359.HK）为全球生物医药行业提供全方位、一体化的新药研发和生产服务。通过赋能全球制药、生物科技和医疗器械公司，药明康德致力于推动新药研发进程，为患者带来突破性的诊疗方案。本着以研究为首任，以客户为中心的宗旨，药明康德通过高性价比和高效的研发服务，助力客户提升研发效率，服务范围涵盖化学药研发和生产、细胞及基因疗法研发生产、医疗器械测试等领域。目前，药明康德的赋能平台正承载着来自全球30多个国家的3700多家合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患，早日实现“让天下没有难做的药，难治的病”的愿景。更多信息，请访问公司网站：www.wuxiapptec.com

Dr. Ge Li Awarded “CEO of the Year” at CPhI Worldwide 2019

November 11, 2019: WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, announced today that its Chairman and CEO Dr. Ge Li was awarded “CEO of the Year” at the CPhI Worldwide 2019, a top pharmaceutical event uniting over 45,000 professionals worldwide.

The 2019 CPhI Pharma Awards recognize the innovation and dedication of companies and individuals who are driving the pharmaceutical industry forward. Its Judging Panel is comprised of independent, senior industry experts from around the world, each chosen for their knowledge, objectivity and credibility.

Dr. Ge Li was chosen for his significant contribution to the global biopharma R&D industry. “Under his leadership, WuXi AppTec has become a highly respected contributor to global healthcare innovation. The company is enabling more than 3,700 customers and partners in more than 30 countries by offering open-access capabilities and services, accelerating the discovery and development of new medicines for patients around the world.”

“I’m honored by this award and its recognition of WuXi’s global platform,” said Dr. Ge Li, Chairman and CEO of WuXi AppTec. “It’s been our great privilege to serve our innovative partners around the world and help bring some of the most needed medicines closer to patients.”

About WuXi AppTec
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 3,700 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated." Please visit: http://www.wuxiapptec.com.

药明康德董事长李革博士荣获CPhI“2019年度CEO”

正文

请到「今天看啥」查看全文